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The CNS melanocortin (MC) system is implicated as a mediator
of the central effects of leptin, and reduced activity of the CNS
MC system promotes obesity in both rodents and humans.
Because activation of CNS MC receptors has direct effects on
autonomic outflow and metabolism, we hypothesized that food
intake-independent mechanisms contribute to development of
obesity induced by pharmacological blockade of MC receptors
in the brain and that changes in hypothalamic neuropeptidergic
systems known to regulate weight gain [i.e., corticotropin-
releasing hormone (CRH), cocaine–amphetamine-related tran-
script (CART), proopiomelanocortin (POMC), and neuropeptide
Y (NPY)] would trigger this effect. Relative to vehicle-treated
controls, third intracerebroventricular (i3vt) administration of the
MC receptor antagonist SHU9119 to rats for 11 d doubled food
and water intake (toward the end of treatment) and increased
body weight (;14%) and fat content (;90%), hepatic glycogen
content (;40%), and plasma levels of cholesterol (;48%),
insulin (;259%), glucagon (;80%), and leptin (;490%),
whereas spontaneous locomotor activity and body temperature
were reduced. Pair-feeding of i3vt SHU9119-treated animals to
i3vt vehicle-treated controls normalized plasma levels of insu-
lin, glucagon, and hepatic glycogen content, but only partially
reversed the elevations of plasma cholesterol (;31%) and lep-
tin (;104%) and body fat content (;27%). Reductions in body
temperature and locomotor activity induced by i3vt SHU9119
were not reversed by pair feeding, but rather were more pro-
nounced. None of the effects found can be explained by pe-
ripheral action of the compound. The obesity effects occurred
despite a lack in neuropeptide expression responses in the
neuroanatomical range selected across the arcuate (i.e., CART,
POMC, and NPY) and paraventricular (i.e., CRH) hypothalamus.
The results indicate that reduced activity of the CNS MC path-
way promotes fat deposition via both food intake-dependent
and -independent mechanisms.
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With the discovery of leptin by Zhang et al. (1994) and its
receptors in the CNS, a long-sought feedback mechanism was
established linking adiposity to CNS regulation of body weight
homeostasis. The brain melanocortin (MC) system—with
a-melanocyte-stimulating hormone (a-MSH) and agouti-related
protein (AgRP) as agonists and antagonists, respectively, of brain
MC receptors—is implicated in the signaling cascade used by
leptin in the CNS. For example, reduced food intake that occurs
after third intracerebroventricular (i3vt) leptin administration
was effectively blocked by coadministration of the mixed MC3/4-
receptor antagonist SHU9119 (Seeley et al., 1997). In addition,
the stimulatory effects of leptin on uncoupling protein synthesis
in peripheral tissue (Satoh et al., 1998) and sympathetic renal
nerve traffic (Haynes et al., 1999) was shown to be blocked by
central MC receptor antagonism. Complementary to these effects
were findings by our (Schwartz et al., 1997; van Dijk et al., 1999)
and other groups (Thornton et al., 1997) that leptin stimulates
proopiomelanocortin (POMC; precursor peptide from which
a-MSH is cleaved) synthesis in neuronal cell bodies of the arcuate
hypothalamic nucleus.
In concert with the notion that brain melanocortins are in-
volved in leptin signaling are observations that overproduction of
the endogenous MC receptor antagonist agouti, or AgRP (Yen et
al., 1994; Miltenberger et al., 1997), and targeted mutations of
MC receptors (Huszar et al., 1997) or of POMC (Yaswen et al.,
1999) lead to hyperphagia and increased fat deposition in rodents,
and thus play an essential role in energy homeostasis. Conse-
quences of reduced MC receptor activity may be clinically rele-
vant because both polymorphisms (Comuzzie et al., 1997; Hixson
et al., 1999) and mutation (Krude et al., 1998) of the POMC gene
locus, as well as mutation of MC4 receptors (Hinney et al., 1999;
Cheng and Garg, 1999; Gu et al., 1999), are linked with human
obesity. Pharmacological evidence for a role of MC receptors in
body weight homeostasis in rats was provided by Skuladottir et al.
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(1999), who reported that 7 d i3vt treatment with the MC4-R
antagonist HS014 increases food intake and body weight.
Because CNS MC receptor activation increases metabolic rate
(Cornelius et al., 1999), we hypothesized that weight gain induced
by central blockade of MC receptors is mediated by both food
intake-dependent and -independent mechanisms. Such a food
intake-independent contribution to obesity has recently been
observed in MC4 knock-out mice (Ste. Marie et al., 2000). To test
this hypothesis, rats were infused i3vt (or peripherally) either
with SHU9119 or vehicle over an 11 d period using osmotic
minipumps. Meanwhile, effects on food and water intake, body
weight and temperature, spontaneous activity, and stored and
circulating levels of fuels and hormones were assessed. An addi-
tional group of i3vt SHU9119-treated animals was pair-fed to
controls such that the amount of food provided to these animals
was equal to the amount consumed by the vehicle-treated group.
This pair-fed group permitted investigation of the effects of
reduced CNS MC receptor activity on energy balance via mech-
anisms independent of food intake.
In addition to a-MSH, a number of other hypothalamic neu-
ropeptides are known to be involved in the regulation of energy
balance. These include, for example, corticotropin-releasing hor-
mone (CRH) (Hotta et al., 1991; Buwalda et al., 1997), neuropep-
tide Y (NPY) (Stanley et al., 1986; Zarjevski et al., 1993), and
cocaine–amphetamine-related transcript (CART) (Kristensen et
al., 1998). The activity of these neuropeptide systems is controlled
by leptin (for review, see Schwartz et al., 2000), and possibly by
melanocortins as well (Kesterson et al., 1997; Kask et al., 1998;
Marsh et al., 1999; King et al., 2000). We hypothesized that
chronic i3vt SHU9119 treatment can stimulate orexigenic and/or
inhibit anorexigenic pathways, therefore hypothalamic expression
levels of CRH, CART, NPY, and POMC were assessed relative
to vehicle-treated controls.
MATERIALS AND METHODS
Animal preparation. Adult male Wistar rats obtained from the breeding
colony maintained by the Department of Animal Physiology at the
University of Groningen, weighing between 420 and 470 gm (between 5
and 6 months of age) were used. They were individually housed in
Plexiglas cages (25 3 25 3 30 cm) on a layer of wood shavings, under
controlled temperature (21 6 1°C), relative humidity (55–5%), and
maintained on a 12 hr light /dark cycle (lights on 5:00 A.M. to 5:00 P.M.).
Animals were handled daily and weighed just before lights off. Food and
water were provided ad libitum except where noted, and their intake was
assessed daily. All methods and experiments were approved by the
Animal Care Committee of the University of Groningen. Under N2O–
halothane anesthesia, rats were implanted stereotaxically with a 22 gauge
stainless steel guide cannula (Plastics One, Roanoke, VA) into the third
ventricle (i3vt) as described elsewhere (van Dijk et al., 1996). Transmit-
ters (model TA10TA-F40; Data Sciences, St. Paul, MN) for the mea-
surement of body temperature and activity by radio telemetry were also
implanted in the peritoneal cavity. Individual cages of animals were
arranged on a radio receiver (model RA1010; Data Sciences), each
attached via a BCM-100 consolidation matrix to a computerized data
acquisition system (Dataquest IV, Data Sciences). This system allowed
continuous assessment of body temperature and locomotor activity until
the end of the experiment. After surgery, each rat received natrium-
benzylpenicillin (100,000 IU) and was allowed to recover for at least 10 d.
After they had regained normal growth rates and normal food and
water intake for at least 1 week, animals (n 5 14) were semirandomly
divided into two groups that had the same mean body weight. Approx-
imately 1 hr before the dark phase, each rat (under N2O–halothane
anesthesia) had a osmotic minipump (Alzet 2002; Alza, Palo Alto, CA;
pumping rate 0.55 ml /hr) implanted subcutaneously and connected with
a polyethylene tube (PE50) to an injector permanently placed into the
guide cannula. In one group (n 5 7), the pumps and connector tubing
were filled to deliver sterile saline, whereas in the other group (n 5 7) the
pumps were filled to deliver SHU9119 (Fan et al., 1997) dosed at 0.5
nmol/d with sterile saline as vehicle. After several days, a third group of
animals (n 5 7) matched for body weight to the control group was
implanted with osmotic minipumps that were filled to deliver SHU9119
(0.5 nmol/d) as well. Each animal in this group received the same amount
of food consumed by a control rat to which they were paired during the
study. Food was given to these pair-fed rats at the beginning of the dark
phase, 4 hr later, and at the end of the overnight period. An additional
group of animals received osmotic minipumps implanted in the abdom-
inal cavity to deliver either saline (n 5 5) or 0.5 nmol SHU9119/d (n 5
5). These groups served to investigate whether any effect of SHU9119 on
body weight, food intake, body temperature, and plasma hormone and
fuel levels could be attributed to leakage of centrally administered
SHU9119 to the periphery.
Assessment of food and water consumption and body weight. Starting 2 d
before implantation of pumps, food hoppers were weighed at the begin-
ning of the dark period, 4 hr after, and at the end of the overnight period
to assess food intake over the first 4 hr of the dark phase, the final 8 hr
of the dark phase, and the food intake that occurred during the light
phase. Water bottles and rats were weighed just before the dark phase. At
the beginning of the dark phase, at 4 hr into the dark phase and at the
beginning of the light phase, pair-fed animals were provided with the
same amount of chow that was consumed by the ad libitum feeding
controls over the corresponding time intervals.
Body temperature and activity. Body temperature and gross locomotor
activity were recorded by the biotelemetry system during the 2 d of basal
(day 22/21) until the end of the experiment. The transmitter implanted
intraperitoneally produced a temperature-dependent frequency-modulated
signal received by the radio receiver located under the cage. Body temper-
ature was sampled for 10 sec every 5 min, whereas activity was recorded
continuously and sampled at 5 min intervals.
Locomotor activity was measured by monitoring the changes in the
receiver signal strength that resulted from animal movement. To avoid
differences in receiver sensitivity, the mean activity count value of the 2 d
basal recording for each animal was considered as 100% activity for that
animal. Activity counts were expressed as percentage of that value, and
group averages were calculated on transformed data.
Blood and tissue collection and analyses. At the end of the dark cycle of
day 10, animals were taken from their home cages, anesthetized by brief
(,2 min) exposure to CO2, and killed by decapitation. Immediately
thereafter, brains were removed, and liver biopsies were taken and stored
at 280°C. Trunk blood was collected in ice-cooled borosilicate tubes
containing 350 ml of aprotinin, 10,000 IU/ml, and EDTA 0.05 gm/ml.
Plasma samples (after centrifugation for 15 min 15003g 4°C) were stored
at 280°C. Blood glucose levels were measured by the ferricyanide
method of Hoffman; plasma level of insulin, glucagon and leptin were
measured by commercial radioimmunoassay kits (Linco Research; RI-
13K, GL-32K, and RL-83K, respectively), plasma concentrations of
triglycerides, free fatty acids, and total cholesterol were measured using
commercial kits (Boehringer Mannheim, Mannheim, Germany), and
plasma corticosterone was measured using HPLC with UV detector
according to Dawson et al. (1984). Liver glycogen biopsies were cut
(25–50 mg) from frozen tissue, boiled for 2 hr in 1 M HCl to facilitate
glycogen breakdown. After pH neutralization, glucose concentrations
were assessed in these samples, indicating the amount of initial glycogen
in tissue.
Wet weight of eviscerated carcasses, livers, retroperitoneal and epi-
didymal fat pads, and intestines including stomach (with and without
contents) were assessed and stored at 75°C for several weeks. Fat content
of eviscerated carcasses and different organs was determined by compar-
ing dry weight before and after fat extraction with petroleum-ether
(Leshner et al., 1972).
In situ hybridization. Brains were removed immediately after decapi-
tation between 8:00 A.M. and 12:00 P.M., frozen in a bed of crushed dry
ice, sectioned in a coronal plane at 14 mm with a cryostat, mounted on
RNase-free slides, and treated with 4% paraformaldehyde, acetic anhy-
dride, ethanol, and chloroform. For each animal, four to six slides (12
brain sections) containing hypothalamus were selected for hybridization.
All brain slices were concurrently prepared for hybridization and used in
the same assay for each probe. Riboprobes for peptide mRNAs were
transcribed in the presence of 33P-UTP from cDNA templates for NPY,
CRH, POMC, and CART. Unincorporated label was separated using a
QIAquick nucleotide removal kit (Qiagen, Santa Clarita, CA). Melting
temperature calculations assume that the transcription reaction produced
full-length transcripts. Hybridization to CRH mRNA was performed on
sections from the paraventricular nucleus. For hybridization to NPY
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mRNA, sections were selected from the midregion of the rostrocaudal
extent of the arcuate nucleus (which also contains the dorsomedial and
ventromedial nuclei), based on our previous experience that NPY
mRNA responses to fasting (Marks et al., 1992) and to leptin (Schwartz
et al., 1996) are especially robust in this area. For similar reasons,
sections for POMC mRNA were selected from the rostral ARC
(Schwartz et al., 1997), whereas CART mRNA hybridization was per-
formed on sections from the midregion of the arcuate nucleus adjacent to
those selected for NPY. Where possible, hybridization to NPY mRNA
was also determined in the hypothalamic dorsomedial nucleus.
Quantitation. The hybridization signal in the ARC of each brain slice
was determined from autoradiograms using a phosphoimager system that
measures the product of the density and area of the hybridization signal.
For each section, the background hybridization signal (measured in an
area of the hypothalamus without specific hybridization) was subtracted
from the value measured in the target area (e.g., in the arcuate nucleus).
The resultant mRNA hybridization value reported for each animal is the
mean of 8–12 sections measured per animal. The anatomical equivalence
of hypothalamic sections among animals was obtained by selecting slides
(viewed with a dark-field stereomicroscope) with the aid of a rat brain
atlas before hybridization. Values of mRNA for each animal are ex-
pressed as percentage of the mean value of the vehicle-treated controls
fed ad libitum.
Statistical analyses. Results are presented as mean 6 SEM, two-way
ANOVA was used for analyses of body weight, food and water intake,
core temperature, and locomotor activity, with treatment conditions as
between-subject factors (vehicle vs SHU9119 vs SHU9119/pair-fed) and
time as repeated measures (13 factors: days 22/10). Further data analysis
included standard one-way ANOVA with three levels (vehicle vs
SHU9119 vs SHU9119/pair-fed), and a post hoc t test for independent
measures was used to test the significance at each time point ( p , 0.05).
A paired sample t test for dependent measures was used to test signifi-
cance ( p , 0.05) between body temperature and locomotor activity
assessed during baseline and during treatment. Pearson’s test was used to
detect significant correlation between body temperature and locomotor
activity of the last 5 d of treatment and between plasma levels of leptin
and expression levels of various hypothalamic neuropeptides.
RESULTS
Food and water consumption and body weight
The effect of chronic i3vt administration of SHU9119 on daily
food intake (A) and body weight (B) changes are shown in Figure
1. ANOVA revealed significant interaction effects on food intake
(time 3 treatment: F(22,198) 5 13.0; p , 0.0001) and body weight
(time 3 treatment: F(24,216) 5 24.0; p , 0.0001). Post hoc analyses
revealed that food intake as well as body weight were dramatically
increased in the ad libitum fed SHU9119-treated group relative to
vehicle controls. ANOVA revealed significant interaction effects
on water intake (time 3 treatment: F(22,198) 5 10.1; p , 0.0001;
data not shown) that appeared to follow the changes in food
intake. No differences were observed between body weights of
vehicle-treated and SHU9119-treated rats that were pair-fed to
controls. Intraperitoneally implanted pumps delivering SHU9119
in a dose equal to that given centrally did not alter food intake
(F(10,80) 5 0.746; p 5 0.679), water intake (F(10,80) 5 1.17; p 5
0.323) and body weight (F(10,80) 5 0.887; p 5 0.549) relative to
animals treated intraperitoneally with saline.
Body composition
Table 1 shows body composition of i3vt vehicle-treated, SHU9119-
treated, and SHU9119-treated/pair-fed animals at the beginning of
the light phase on day 11 of treatment. ANOVA revealed effects of
treatment on total body weight (F(2,18) 5 15.5; p , 0.0001), eviscer-
ated carcass wet weight (F(2,18) 5 3.8; p , 0.05), and weights of the
liver (F(2,18) 5 34.05; p , 0.0001), gastrointestinal tract (F(2,18) 5
25.28; p , 0.0001), and gastrointestinal filling (F2,18 528.11; p ,
0.0001), which were only significantly higher in the SHU9119-
treated animals relative to controls. Weights of retroperitoneal
(F(2,18) 5 26.4; p , 0.0001) and epididymal (F(2,18) 5 8.3; p ,
0.001) fat pads were higher in both SHU9119-treated and
SHU9119-treated/pair-fed animals relative to controls. Table 2
shows results of fat extraction analyses. Fat content of the eviscer-
ated carcass (F(2,18) 5 35.67; p , 0.0001), liver (F(2,18) 5 13.30; p ,
0.0001), and gastrointestinal tract (F(2,18) 5 55.73; p , 0.0001)
were only increased in the SHU9119-treated ad libitum-fed
animals relative to those in vehicle-treated controls, but not in
SHU9119 treated/pair-fed animals. Fat content of abdominal fat
pads (F(2,18) 5 25.99; p , 0.0001) and body fat content expressed
as absolute fat mass of total body (F(2,18) 5 47.36; p , 0.0001) and
expressed as percentage of body fat of total body (F(2,18) 5 49.60;
p , 0.0001) were higher in both SHU9119-treated and SHU9119-
treated/pair-fed animals relative to controls. Thus, SHU9119 in-
creased body fat content over vehicle-treated animals consuming
the same amount of food. Intraperitoneal SHU9119 treatment did
not alter any of these parameters relative to animals intraperito-
neally treated with saline.
Temperature and locomotor activity
From day 5 on, body temperature of vehicle-treated animals
during the light phase had returned to preinfusion levels, indi-
cating recovery from the effect of pump implantation. Mean
values of both temperature and activity measured in the light and
dark cycles from day 5–10 for each group are shown in Figure 2.
Although vehicle treatment tended to increase the activity level
during the dark and light phase, this effect was not significant
when analyzed by a paired sample t test comparing preinfusion
activity levels with those obtained over days 5–10. The slight
increase was mainly attributable to two animals, which, in the
event of exclusion from the ANOVA, did not primarily affect the
outcome of treatment effects across all groups. During the dark
phase, ANOVA revealed a significant effect on body temperature
(F(2,18) 5 20.3; p , 0.0001) and locomotor activity (F(2,18) 5 6.2;
p 5 0.009). Post hoc analyses revealed that body temperatures of
SHU9119-treated ad libitum-fed animals ( p , 0.0001) as well as
of SHU9119-treated/pair-fed animals ( p , 0.0001) were signifi-
cantly lower than that of vehicle-treated animals during the dark
cycle. No differences were observed between the two SHU9119-
treated groups. Post hoc analysis revealed lower locomotor activ-
Figure 1. Effect of third cerebroventricular (i3vt) treatment for 11 d with
vehicle (saline; n 5 7), SHU9119 (0.5 nmol/d; n 5 7), or SHU9119 (0.5
nmol/d) pair-fed to the vehicle-treated group (SHU9119/pair-fed; n 5 7)
on 24 hr food intake (A) and body weight (B). Both food intake ( p ,
0.0001 from day 2 till the end of treatment) and body weight ( p , 0.05,
days 2–7; p , 0.01, days 8–10) were significantly increased in i3vt
SHU9119-treated animals compared with the i3vt vehicle-treated group.
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ity ( p 5 0.007) of SHU9119-treated pair-fed animals relative to
that of vehicle control animals. ANOVA also revealed significant
effects of treatments on the 5 d averages of body temperature
(F(2,18) 5 7.8; p 5 0.004) and locomotor activity (F(2,18) 5 4.4; p 5
0.027) during the light phase. SHU9119-treated/pair-fed animals
had a lower light phase temperature relative to SHU9119-treated
ad libitum animals ( p 5 0.009) as well as relative to controls ( p 5
0.008). Only locomotor activity displayed by the pair-fed group
was lower ( p 5 0.038) than that displayed by controls. Intraperi-
toneal SHU9119 treatment did not alter body temperature
(F(1,8) 5 1.889; p 5 0.207) and activity (F(1,8) 5 2.777; p 5 0.134)
during the light phase nor during the dark phase (F(1,8) 5 0.944;
p 5 0.360 and F(1,8) 5 0.012; p 5 0.917 for temperature and
activity, respectively) of animals relative to these parameters in
animals treated intraperitoneally with saline.
Pearson’s test revealed a significant correlation of body tem-
perature with locomotor activity of animals across all treatment
groups during the dark phase (r 5 0.63; p 5 0.01), but not in the
light phase (r 5 0.34; NS).
Plasma analyses
Table 3 shows the plasma concentrations of fuels and hormones
and the hepatic glycogen content of i3vt vehicle-treated,
SHU9119-treated, and SHU9119-treated/pair-fed animals at the
beginning of the light phase on the last day of treatment. ANOVA
revealed significant treatment effects on plasma levels of insulin
(F(2,18) 519.9; p , 0.0001), glucagon (F(2,18) 5 21.8; p , 0.0001),
leptin (F(2,18) 5 68.0; p , 0.0001), cholesterol (F(2,18) 5 14.78; p ,
0.0001), and on total hepatic glycogen content (F(2,18) 5 6.1; p ,
0.01). No treatment effects were found on plasma levels of tri-
glycerides, free fatty acids, corticosterone, and glucose. Post hoc
analysis revealed that, relative to vehicle-treated animals,
SHU9119-treated rats have higher levels of plasma cholesterol,
leptin, insulin, glucagon, and total hepatic glycogen. Relative to
vehicle-treated controls, plasma cholesterol and leptin levels were
also elevated in SHU9119-treated animals that were pair-fed to
controls. Intraperitoneal SHU9119 treatment failed to have an
effect on any of these parameters relative to intraperitoneal or
i3vt saline treatment.
In situ hybridization
Figure 3 shows the results of in situ hybridization (presented as
percentage of expression of mean value of the vehicle-treated
group) of mRNA for NPY, POMC, and CART in the arcuate
Table 1. Body composition of experimental rats
Treatment Vehicle SHU9119 SHU9119/pair-fed
Total weight 450.1 6 8.2 512.3 6 7.7*** 449.5 6 11.3
Eviscerated carcass 364.6 6 6.7 387.2 6 5.1* 361.8 6 9.2
Liver 15.5 6 0.4 21.0 6 0.8** 15.0 6 0.5
Gastrointestinal tract (empty) 17.9 6 0.8 26.9 6 1.3*** 19.9 6 0.7
Gastrointestinal filling 17.6 6 1.6 37.7 6 2.5*** 19.1 6 2.1
Retroperitoneal fat 4.5 6 0.8 11.2 6 0.7*** 6.7 6 0.5*
Epididymal fat 7.4 6 0.6 10.9 6 0.6*** 9.3 6 0.7*
Wet weights are means 6 SE expressed in grams. Rats received third cerebroventricular (i3vt) treatment for 11 d with vehicle
(saline; n 5 7), SHU9119 (0.5 nmol/d; n 5 7), or SHU9119 (0.5 nmol/d) pair-fed with the vehicle-treated group
(SHU9119/pair-fed; n 5 7). *p , 0.05; **p ,0.01, and ***p ,0.001 denote statistical difference with the i3vt vehicle-treated
group.
Table 2. Fat contents after fat extraction procedure
Treatment Vehicle SHU9119 SHU9119/pair-fed
Total body fat 46.6 6 3.3 96.4 6 2.7*** 59.0 6 5.0*
Total fat as % body weight 10.8 6 0.7 20.3 6 0.5*** 13.6 6 0.9*
Eviscerated carcass 31.8 6 2.9 66.0 6 2.3*** 39.9 6 3.7
Liver 0.6 6 0.3 1.6 6 0.2** 0.3 6 0.1
Gastrointestinal tract 4.9 6 0.4 9.5 6 0.3*** 5.5 6 0.4
Abdominal fat pads 9.4 6 1.0 19.4 6 0.9*** 13.3 6 1.0*
Weights are means 6 SE expressed in grams. Rats received third cerebroventricular (i3vt) treatment for 11 d with vehicle
(saline; n 5 7), SHU9119 (0.5 nmol/d; n 5 7), or SHU9119 (0.5 nmol/d) pair-fed with the vehicle-treated group
(SHU9119/pair-fed; n 5 7). *p,0.05, **p,0.01, and ***p,0.001) denote statistical difference with the i3vt vehicle-treated
group.
Figure 2. Five day averages (days 5–10 after minipumps implantation) of
body temperature (A) and locomotor activity (B) during the dark and
light phase of rats treated third cerebroventricularly (i3vt) with vehicle
(saline; n 5 7), SHU9119 (0.5 nmol/d; n 5 7), or SHU9119 (0.5 nmol/d)
pair-fed with the vehicle-treated group (SHU9119/pair-fed, n 5 7). *p ,
0.05); **p , 0.01; ***p , 0.001 denote statistical difference with the i3vt
vehicle-treated group. 11p , 0.01 denotes statistical difference with the
i3vt SHU9119-treated group.
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hypothalamic nucleus and for CRH in the paraventricular nucleus
of i3vt vehicle-treated, SHU9119-treated, and SHU9119-treated/
pair-fed animals at the beginning of the light phase on day 11 of
treatment. No NPY mRNA expression was observed in the dor-
somedial hypothalamic nucleus.
Overall ANOVAs did not reveal statistical significant differ-
ences in expression levels of NPY, POMC, CART, or CRH
mRNA across all groups. However, consistent with regulatory
effects of leptin on the expression profiles of these neuropeptides,
Pearson’s test revealed significant positive correlations of plasma
leptin of animals across the three treatment groups with expres-
sion of prepromRNA for CRH (r 5 0.51; p 5 0.03), CART (r 5
0.49; p 5 0.04), and POMC (r 5 0.50; p 5 0.03).
DISCUSSION
The present study investigated the effect of 11 d of third intra-
cerebroventricular (i3vt) administration of the MC receptor (type
3 and 4) antagonist SHU9119 on various behavioral, hormonal–
metabolic, and neuroendocrine mechanisms important to regula-
tion of energy balance. As predicted, i3vt SHU9119 treatment
produced, in rats allowed to augment their food intake, a dra-
matic increase of body weight (;14%) and plasma leptin levels
(;490%) relative to controls. The increase in body weight in
SHU9119-treated animals relative to controls was primarily at-
tributable to markedly increased (;90%) fat deposition. The
doubling of food intake in SHU9119-treated animals obviously
contributed importantly to their weight gain. By including a group
of SHU9119-treated animals that was pair-fed to vehicle-treated
controls, we were able to distinguish those responses to chronic
MC receptor blockade from the ones that were secondary to the
increased food intake. For example, although SHU9119 treat-
ment led to increased levels of plasma insulin, glucagon, and
hepatic glycogen content relative to those in controls, these values
were caused by overfeeding because they were normalized by pair
feeding of i3vt SHU9119-treated animals to vehicle-treated con-
trols. Some responses to central MC receptor blockade, however,
were not completely reversed by pair feeding of SHU9119-treated
animals to controls. Although their body weight did not increase
detectably, i3vt SHU9119/pair-fed animals still exhibited a 27%
increase in fat mass (vs 90% increase in ad libitum SHU9119-
treated animals) and a 104% increase in plasma leptin levels (vs
490% in ad libitum SHU9119-treated animals) relative to con-
trols. The increased leptin secretion is likely secondary to the
residual increase seen in the fat depot size in SHU9119-treated/
pair-fed animals relative to controls, if leptin secretion is subject
to autoregulation as part of an “adipostat” pathway.
The most pronounced effects of i3vt SHU9119 treatment that
were independent of increased food intake were reductions in
body temperature and spontaneous activity and an increase in
plasma cholesterol levels (relative to controls: 31 and 48% in-
creases in pair-fed and ad libitum feeding SHU9119-treated ani-
mals, respectively). Although the specific fraction of lipoprotein
cholesterol that was elevated remains to be determined, this is the
first demonstration of a CNS intervention that leads to increased
plasma levels of total cholesterol in genetically normal rats. Given
the importance of high plasma total cholesterol as well as an
obese phenotype in the pathogenesis of artherosclerotic vascular
disease, the possibility that reduced CNS MC receptor signaling
may have relevant clinical consequences can be considered. Be-
cause we did not find an effect of peripheral SHU9119 treatment
on any parameter assessed, we can rule out the possibility that the
central effects that we observed involve an action of melanocortin
receptor blockade in peripheral tissues (i.e., by leakage from the
CNS into the general circulation). Thus, these data strongly
implicate the brain as the site where reduced melanocortin re-
ceptor activity leads to obesity and its associated metabolic
derangements.
Table 3. Plasma concentrations of fuel, hormones, and hepatic glycogen of experimental rats
Treatment Vehicle SHU9119 SHU9119/pair-fed
Glucose, mmol/ l 6.67 6 0.50 7.23 6 0.38 6.18 6 0.28
Triglycerides, mmol/ l 1.57 6 0.20 1.06 6 0.16 1.30 6 0.10
Free fatty acids, mmol/ l 0.25 6 0.02 0.23 6 0.02 0.20 6 0.01
Cholesterol, mmol/ l 1.66 6 0.09 2.45 6 0.10*** 2.18 6 0.13**
Insulin, pmol/ l 0.90 6 0.08 3.21 6 0.48*** 0.98 6 0.16
Glucagon, ng/ l 93.29 6 7.38 169.0 6 8.78*** 97.00 6 5.96
Corticosterone, nmol/ l 103.48 6 39.65 111.81 6 23.51 136.10 6 18.24
Leptin, mg/ l 4.91 6 0.65 29.02 6 2.34*** 10.03 6 1.10**
Total hepatic glycogen, gm 1.09 6 0.06 1.53 6 0.14** 1.09 6 0.09
Values are means 6 SE. Rats received third cerebroventricular (i3vt) treatment for 11 d with vehicle (saline; n 5 7),
SHU9119 (0.5 nmol/d; n 5 7), or SHU9119 (0.5 nmol/d) and were pair-fed with the vehicle-treated group (SHU9119/pair-
fed; n 5 7). **p , 0.01 and ***p , 0.001 denote statistical difference with the i3vt vehicle-treated group.
Figure 3. Expression of mRNA for NPY, CART, and POMC in the
arcuate hypothalamic nucleus, and CRH in the paraventricular nucleus of
rats treated third cerebroventricularly (i3vt) for 11 d with vehicle (saline;
n 5 7; open bars), SHU9119 (0.5 nmol/d; n 5 7; black bars), or SHU9119
(0.5 nmol/d) pair-fed with the vehicle-treated group (SHU9119/pair-fed;
n 5 7; hatched bars). Levels of mRNA were expressed as percentage of
expression of mean value of the vehicle-treated group.
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Our results showing that i3vt SHU9119-treated rats fed ad
libitum as well as SHU9119-treated/pair-fed animals are more
obese and have lower body temperatures relative to controls are
consistent with the recent observation in MC4 receptor knock-
out mice (Ste. Marie et al., 2000). These mice have a metabolic
defect that promotes obesity in a similar manner as the SHU9119-
treated animals in the present study. Because MC3 receptor
knock-out mice have an increased fat depot size (Butler et al.,
2000; Chen et al., 2000), it might be possible that part of the effect
of i3vt SHU9119 to promote obesity is caused via its inhibitory
effect on MC3 receptors. The data in the present study are also
consistent with rodents with mutations in either leptin synthesis
(ob/ob mice) or leptin receptors (db/db mice, fa/fa rats) that are
also obese and hypothermic (Campfield et al., 1995; Seeley et al.,
1996; Halaas et al., 1997). Because leptin can increase energy
expenditure (Halaas et al., 1997; van Dijk et al., 1999), uncoupling
protein synthesis in various peripheral tissues (Halaas et al., 1997;
Scarpace et al., 1997; Zhou et al., 1997), and body temperature
(Halaas et al., 1997) via actions in the CNS, pharmacological
blockade of CNS pathways downstream from leptin signaling
might be expected to lower body temperature, and MC receptor
signaling is implicated in at least some of these responses (Satoh
et al., 1998). Because SHU9119-treated/pair-fed animals had
lower spontaneous activity levels compared with controls, it might
be possible that this effect also contributed to the lower body
temperature of this group. The fact that locomotor activity and
body temperature (particularly during the dark phase when ani-
mals display the greatest spontaneous activity) were strongly
correlated across all treatment groups raises the interesting pos-
sibility that reduced physical activity contributes to increased
weight gain in response to pharmacological blockade of CNS MC
receptors.
Within the anatomical range across the arcuate and the para-
ventricular nucleus that we selected, SHU9119 treatment in the
present study failed to significantly alter expression levels of
neuropeptides involved in regulation of energy balance. One
implication of this observation might be that the obese phenotype
as a result of CNS MC3/4 receptor blockade is independent of
some hypothalamic neuropeptide responses (i.e., reduced mRNA
for CRH, POMC, and CART, and increased mRNA for NPY)
anticipated to underlie weight gain. In fact, there were tendencies
of SHU9119 treatment to increase paraventricular hypothalamic
expression of CRH mRNA and arcuate hypothalamic expression
of POMC and CART mRNA relative to control treatment. In
addition, there was a tendency of SHU9119 treatment to reduce
expression of neuropeptide Y mRNA in the arcuate nucleus,
although none of these effects achieved statistical significance.
Because increased CRH (Hotta et al., 1991; Buwalda et al., 1997),
and CART (Kristensen et al., 1998) signaling and reduced NPY
(Myers et al., 1995) signaling all have anorexigenic actions and
promote leanness, these can be considered as compensatory re-
sponses to the positive energy status of the SHU9119-treated
animals. Consistent with this view is the finding in the present
study of significant positive correlations of animals across all
three groups between the plasma leptin concentration and ex-
pression of mRNA encoding for CRH, CART, and for POMC.
Despite careful analysis, there was no evidence of hypotha-
lamic NPY mRNA expression in the dorsomedial hypothalamic
nucleus. This is consistent with a recent study of Singer et al.
(2000), showing that NPY mRNA is only expressed in the dor-
somedial hypothalamus in very young rats and disappears after
30 d of age. Thus, the increased NPY mRNA expression found in
the dorsomedial nucleus of adult genetically obese AY or MC4
receptor knock-out mice (Kesterson et al., 1997) might be species-
specific and not relevant for the etiology of obesity because of
reduced CNS melanocortin signaling in the rat.
In summary, the results of the present study provide clear
additional evidence that inhibition of CNS MC receptor activity
leads to obesity and hypercholesterolemia and that food intake-
independent mechanisms contribute to this phenomenon. The
data furthermore show that hypothermic and attenuated sponta-
neous activity effects of reduced CNS MC receptor activity are
independent of food intake and likely promote increased fat
deposition and increases of plasma leptin levels in pair-fed ani-
mals. In addition, i3vt SHU9119 treatment tended to increase
expression of hypothalamic neuropeptides (at least in the ana-
tomical range that we selected) that promote leanness (CRH,
CART, POMC) and to reduce one that promotes weight gain
(NPY). Thus, these data seem to suggest that the brain melano-
cortin system might not be a pivotal step linking leptin signaling
to altered activity of hypothalamic pathways that contain CRH,
CART, POMC, and NPY. Rather, our findings support the view
that these systems are regulated by leptin in parallel (Boston et
al., 1997) and that interventions that influence energy balance via
one pathway elicit compensatory responses from the others.
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